ADS-ADEA 2015* Sabina Furber
Novo Nordisk, NSW, Australia
- This delegate is presenting an abstract at this event.
- Trade
Presentations this author is a contributor to:
Additional analyses of the weight-lowering efficacy of liraglutide 3.0 mg in overweight and obese adults: the SCALE Obesity and Prediabetes randomised trial (#10)
9:30 AM
Joseph Proietto
ADS Clinical Orals: Obesity
Cardiovascular safety of liraglutide: meta-analysis of major adverse cardiovascular events (MACE) across weight management and T2D development programs (#310)
2:00 PM
Ian D Caterson
ADS Clinical Poster Viewing: Treatment
Liraglutide 3.0 mg: weight-loss dependent and independent effects (#305)
2:00 PM
Luc van Gaal
ADS Clinical Poster Viewing: Treatment